Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Dizal announces positive pooled data of sunvozertinib in EGFR TKI-resistant NSCLC: Shanghai, China Friday, December 13, 2024, 18:00 Hrs [IST] Dizal, a biopharmaceutical company co ...

In the conclusion to our interview with Joshua K. Sabari, MD, which focused on the first-line approval of amivantamab (Ami; ...

Abbisko Cayman Limited (HK:2256) has released an update.Pick the best stocks and maximize your portfolio:Discover top-rated stocks from highly ...

The FDA has granted Breakthrough Therapy Designation to datopotamab deruxtecan (Dato-DXd) for advanced EGFR-mutated non-small cell lung cancer.

US FDA grants breakthrough therapy designation to datopotamab deruxtecan for patients with previously treated advanced EGFR-mutated NSCLC: Cambridge, UK Tuesday, December 10, 2024 ...

Precision medicine is an innovative approach that tailors treatment to the unique genetic and molecular characteristics of a ...

【导读】这项研究评估了鞘内培美曲塞（IP）对既往接受过治疗的表皮生长因子受体（EGFR）突变晚期非小细胞肺癌（NSCLC）患者脑膜转移瘤（LM）的治疗效果。2024年12月7日，中南大学湘雅医学院附属肿瘤医院张永昌教授团队在期刊《Heliyon》上发 ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the Phase 3 KEYLYNK-001 trial ...

Among Taiwan’s non-small cell lung cancer cases, approximately 55 percent involve an EGFR mutation, with deletion of exon 19 and exon 21 the most common mutations, treatable with first to ...

Martin Dietrich, MD, PhD, discusses how the FDA-approved combination therapy is transforming care for resectable early-stage ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...